MedTrace Logo

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study

NCT04609111 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6002

Last updated 2024-06-14

No results posted yet for this study

Summary

The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous coronary intervention (PCI) using cobalt-chromium everolimus-eluting stents (CoCr-EES, XienceTM) in patients with high bleeding risk or under the acute coronary syndrome patients.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

No aspirin

1-month prasugrel monotherapy followed by clopidogrel monotherapy

DRUG

1-month DAPT

1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy

Sponsors & Collaborators

  • Kyoto University, Graduate School of Medicine

    lead OTHER

Principal Investigators

  • Takeshi Kimura, MD · Kyoto University, Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-29
Primary Completion
2023-12-31
Completion
2025-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04609111 on ClinicalTrials.gov